Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center

home / authors / alexander-drilon-md-memorial-sloan-kettering-cancer-center

Articles

Rapid Readouts: Results from two trials of TRK inhibitor, larotrectinib, in patients with TRK fusion-positive lung cancer

July 1st 2021

Alexander Drilon, MD presents data from the 2021 American Society of Clinical Oncology annual meeting from trials in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer treated with larotrectinib.

Rapid Readouts: Updated data from a pooled analysis of larotrectinib in TRK fusion-positive cancers

July 1st 2021

Alexander Drilon, MD presents updated results from a pooled analysis of TRK fusion-positive cancers treated with larotrectinib from the 2021 American Society of Clinical Oncology annual meeting.